Samuel Murray

3.9k total citations · 1 hit paper
50 papers, 2.5k citations indexed

About

Samuel Murray is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Cancer Research. According to data from OpenAlex, Samuel Murray has authored 50 papers receiving a total of 2.5k indexed citations (citations by other indexed papers that have themselves been cited), including 28 papers in Pulmonary and Respiratory Medicine, 26 papers in Oncology and 18 papers in Cancer Research. Recurrent topics in Samuel Murray's work include Lung Cancer Treatments and Mutations (19 papers), Cancer Genomics and Diagnostics (16 papers) and Renal cell carcinoma treatment (8 papers). Samuel Murray is often cited by papers focused on Lung Cancer Treatments and Mutations (19 papers), Cancer Genomics and Diagnostics (16 papers) and Renal cell carcinoma treatment (8 papers). Samuel Murray collaborates with scholars based in Greece, United States and United Kingdom. Samuel Murray's co-authors include Issa J Dahabreh, Helena Linardou, P. Kosmidis, Dimitrios Bafaloukos, Fotios Siannis, Christos Papadimitriou, D. Kanaloupiti, George Fountzilas, Evangelos Briasoulis and Menelaos Manoloukos and has published in prestigious journals such as Journal of Clinical Oncology, American Journal of Respiratory and Critical Care Medicine and Cancer.

In The Last Decade

Samuel Murray

48 papers receiving 2.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Assessment of somatic k-RAS mutations as a mechanism associated with resistance to EGFR-targeted agents: a systematic review and meta-analysis of studies in advanced non-small-cell lung cancer and metastatic colorectal cancer

2008 596 citations Helena Linardou, Issa J Dahabreh et al. profile →

Peers

Countries citing papers authored by Samuel Murray

Since Specialization

Citations

This map shows the geographic impact of Samuel Murray's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Samuel Murray with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Samuel Murray more than expected).

Fields of papers citing papers by Samuel Murray

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Samuel Murray. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Samuel Murray. The network helps show where Samuel Murray may publish in the future.

Co-authorship network of co-authors of Samuel Murray

This figure shows the co-authorship network connecting the top 25 collaborators of Samuel Murray. A scholar is included among the top collaborators of Samuel Murray based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Samuel Murray. Samuel Murray is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	1081MO Phase I study of WNT974 in combination with spartalizumab in patients with cutaneous melanoma 2024 ·Annals of Oncology ·(unknown), Jordi Rodon, Filip De Vos, (unknown), M. De Miguel, Iván Márquez‐Rodas, (unknown), (unknown), Michele Del Vecchio, (unknown), Dirk Schadendorf, Rahman Jamal, Steven R. Sloan, Martin McLaughlin, Samuel Murray, (unknown), Emily Han-Chung Hsiue, Sarah Moody, Ana Arance	1
2	Remodeling of the maternal gut microbiome during pregnancy is shaped by parity 2021 ·Microbiome ·Alexander S. F. Berry, (unknown), Ana M. Misic, Megan C. Sullivan, Kevin O’Brien, Ying Chen, Samuel Murray, (unknown), Robert N. Baldassano, Thomas D. Parsons, Daniel P. Beiting	43
3	Everolimus plus bevacizumab is an effective first‐line treatment for patients with advanced papillary variant renal cell carcinoma: Final results from a phase II trial 2020 ·Cancer ·Darren R. Feldman, Yasser Ged, Chung‐Han Lee, Andrea Knežević, Ana M. Molina, Ying‐Bei Chen, Joshua Chaim, Devyn Taylor Coskey, Samuel Murray, Satish K. Tickoo, Victor E. Reuter, Sujata Patil, Han Xiao, Jahan Aghalar, (unknown), Maria I. Carlo, Robert J. Motzer, Martin H. Voss	27
4	Guidance for laboratories performing molecular pathology for cancer patients 2014 ·Journal of Clinical Pathology ·Ian A. Cree, Zandra C. Deans, Marjolijn J. L. Ligtenberg, Nicola Normanno, Anders Edsjö, Étienne Rouleau, Françesc Solé, Erik Thunnissen, Wim Timens, Ed Schuuring, Elisabeth Dequeker, Samuel Murray, Manfred Dietel, Patricia J.T.A. Groenen, J. Han van Krieken	154
5	Molecular predictors of response to tyrosine kinase inhibitors in patients with Non-Small-Cell Lung Cancer 2012 ·Journal of Experimental & Clinical Cancer Research ·Samuel Murray, Vasilios Karavasilis, Mattheos Bobos, Evangelia Razis, Savvas Papadopoulos, Christos Christodoulou, P. Kosmidis, George Fountzilas	22
6	Evaluation of the Xpert MTB/RIF Assay for the Diagnosis of Pulmonary Tuberculosis in a High HIV Prevalence Setting 2011 ·American Journal of Respiratory and Critical Care Medicine ·Grant Theron, Jonny Peter, Richard N. van Zyl-Smit, Hridesh Mishra, Elizabeth M. Streicher, Samuel Murray, Rodney Dawson, Andrew Whitelaw, Michael Höelscher, Surendra K. Sharma, Madhukar Pai, Robin M. Warren, Keertan Dheda	243
7	TP53 Arg72Pro Polymorphism and Colorectal Cancer Risk: A Systematic Review and Meta-Analysis 2010 ·Cancer Epidemiology Biomarkers & Prevention ·Issa J Dahabreh, Helena Linardou, Peggy Bouzika, Vasileia Varvarigou, Samuel Murray	39
8	All about KRAS for clinical oncology practice: Gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer 2010 ·Cancer Treatment Reviews ·Helena Linardou, Evangelos Briasoulis, Issa J Dahabreh, Giannis Mountzios, Christos Papadimitriou, Savvas Papadopoulos, Dimitrios Bafaloukos, P. Kosmidis, Samuel Murray	42
9	EGFR gene copy number as a predictive biomarker for patients receiving tyrosine kinase inhibitor treatment: a systematic review and meta-analysis in non-small-cell lung cancer 2010 ·Annals of Oncology ·Issa J Dahabreh, Helena Linardou, P. Kosmidis, Dimitrios Bafaloukos, Samuel Murray	56
10	Low frequency of somatic mutations in uterine sarcomas: A molecular analysis and review of the literature 2010 ·Mutation research. Fundamental and molecular mechanisms of mutagenesis ·Samuel Murray, Helena Linardou, Giannis Mountzios, Menelaos Manoloukos, S. Markaki, Evangelos Eleutherakis‐Papaiakovou, Meletios Α. Dimopoulos, Christos Papadimitriou	15
11	Somatic EGFR mutations and efficacy of tyrosine kinase inhibitors in NSCLC 2009 ·Nature Reviews Clinical Oncology ·Helena Linardou, Issa J Dahabreh, Dimitrios Bafaloukos, P. Kosmidis, Samuel Murray	192
12	Somatic Mutations of the Tyrosine Kinase Domain of Epidermal Growth Factor Receptor and Tyrosine Kinase Inhibitor Response to TKIs in Non-small Cell Lung Cancer: An Analytical Database 2008 ·Journal of Thoracic Oncology ·Samuel Murray, Issa J Dahabreh, Helena Linardou, Menelaos Manoloukos, Dimitrios Bafaloukos, P. Kosmidis	116
13	Increased Vascular-Endothelial Growth Factor (VEGF) Tumor Expression and Response to Epidermal Growth Factor Receptor (EGF-R) Inhibitor Erlotinib in Non-small Cell Lung Cancer (NSCLC) 2008 ·Journal of Thoracic Oncology ·Wolfgang M. Brueckl, (unknown), Ralph M. Wirtz, Samuel Murray, Eckhart G. Hahn, Gunther H. Wiest	6
14	HLA Class II Alleles and the Presence of Circulating Epstein-Barr Virus DNA in Greek Patients with Nasopharyngeal Carcinoma 2008 ·Strahlentherapie und Onkologie ·Charisios Karanikiotis, (unknown), (unknown), (unknown), Theofanis Economopoulos, Samuel Murray, Demetris Papamichael, E. Samantas, (unknown), Lemonia Skoura, Nikolaos Tselis, Nikolaos Zamboglou, George Fountzilas	8
15	Molecular genetic tools shape a roadmap towards a more accurate prognostic prediction and personalized management of cancer 2007 ·Cancer Biology & Therapy ·Dimitrios H Roukos, Samuel Murray, Evangelos Briasoulis	44
16	‘Classical’ but not ‘other’ mutations of EGFR kinase domain are associated with clinical outcome in gefitinib-treated patients with non-small cell lung cancer 2007 ·British Journal of Cancer ·Athanasios Pallis, Alexandra Voutsina, (unknown), John Souglakos, Evangelos Briasoulis, Samuel Murray, Anastasios Koutsopoulos, (unknown), Efstathios N. Stathopoulos, D. Mavroudis, Vassilis Georgoulias	74
17	Mutations of the epidermal growth factor receptor tyrosine kinase domain and associations with clinicopathological features in non-small cell lung cancer patients 2006 ·Lung Cancer ·Samuel Murray, Eleni Timotheadou, Helena Linardou, (unknown), Ioannis Kostopoulos, Jana Skřičková, (unknown), C. Christodoulou, Dimitrios Pectasides, Epaminontas Samantas, Pavlos Papakostas, Dimosthenis Skarlos, P. Kosmidis, George Fountzilas	28
18	Optimisation of acid fast smears for the direct detection of mycobacteria in clinical samples 2003 ·Journal of Clinical Pathology ·Samuel Murray, (unknown), (unknown), (unknown)	26
19	Reduction of streptavidin RYDS-mediated renal adhesion by site-directed mutagenesis 2002 ·Biochimica et Biophysica Acta (BBA) - General Subjects ·Samuel Murray, Anthony Maraveyas, (unknown), Anthony C. Chu	9
20	Improving tumour targeting and decreasing normal tissue uptake by optimizing the stoichiometry of a two-step biotinylated-antibody/streptavidin-based targeting strategy: Studies in a nude mouse xenograft model 1998 ·International Journal of Cancer ·Anthony Maraveyas, Gail Rowlinson‐Busza, Samuel Murray, Agamemnon A. Epenetos	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact